(Q38384741)

2 September 2017

1 reference

title

Palbociclib: first global approval (English)

1 reference

2 September 2017

1 reference

ChEBI release 2020-05-28

1

Sohita Dhillon

1 reference

2 September 2017

publication date

1 April 2015

1 reference

2 September 2017

1 reference

2 September 2017

volume

75

1 reference

2 September 2017

issue

5

1 reference

2 September 2017

page(s)

543-551

1 reference

CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0379-9

Molecular pathways: CDK4 inhibitors for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0379-9

Signaling through cyclin D-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0379-9

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0379-9

Targeting cell cycle and hormone receptor pathways in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0379-9

PD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0379-9

A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0379-9

Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0379-9

Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0379-9

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0379-9

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0379-9

Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0379-9

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0379-9

Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors

21 January 2018

1 reference

12 December 2020

PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity

1 reference

12 December 2020

CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment

1 reference

12 December 2020

Palbociclib: an evidence-based review of its potential in the treatment of breast cancer

1 reference

12 December 2020

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.

1 reference

12 December 2020

10.1007/S40265-015-0379-9

Identifiers

DOI

1 reference

Dimensions Publication ID

2 September 2017

1043117739

0 references

1 reference